

CURRICULUM VITAE

BIOGRAPHICAL

NAME	Gloria Formoso, M.D.; Ph.D.		
HOME ADDRESS	Via F. Cilea, 29 (Chieti) I - 66100 - ITALY	BIRTH DATE	March 11, 1975
		BIRTH PLACE	Lecce, ITALY
		CITIZENSHIP	Italian
Mobile PHONE	39 347 5206232		
BUSINESS ADDRESS	Edificio CAST (ex CeSI-Met) room 271 Campus Università d'Annunzio Via Luigi Polacchi, 11-13 66100 CHIETI ITALY		
BUSINESS PHONE	39 0871 541305		
E. MAIL	gloria.formoso@unich.it		

EDUCATION AND TRAINING

Date attended	Name and Location of Institution	Degree Received
1995-2000	University of Chieti, Italy	Laurea in Medicine
2001-2005	University of Chieti, Italy School of Medicine	Metabolism Pathophysiology Ph.D. Fellowship
2003-2005	Nation Institute of Health Bethesda, MD, USA	Research Fellowship in Diabetes and Metabolism
2006-2011	University of Chieti School of Medicine	Endocrinology and Metabolism Specialty Degree Summa Cum Laude

ACCADEMIC APPOINTMENTS

YEARS	Name and Location of Institution	TITLE
2011-present	University of Chieti, Italy	Assistant Professor of Medicine

OTHER APPOINTMENTS AND POSITIONS

2014 - present	University of Chieti, Italy National Health Service- Pescara Agency, Italy	Physician Endocrinology and Metabolism Clinic
2016-preset	University of Chieti, Italy	Coordinator

	National Health Service- Pescara Agency, Italy	Ambulatory of Diabetes in Pregnancy
2018-present	University of Chieti, Italy Dpt of Medicine and Aging Sciences	Member of the Research Committee
2019-present	University of Chieti, Italy Dpt of Medicine and Aging Sciences	Member of the Board Committee
Since 2001	Italian Society of Diabetology	Member
2010 - 2014	Italian Society of Diabetology	Member of the Abruzzo Regional Council
Since 2018	Italian Society of Diabetology	Elected President Abruzzo Regional section
Since 2018	Italian Society of Diabetology	Member National Committee of the Diabetes & Pregnancy study group
Since 2014	Italian Society of Endocrinology	Member
Since 2017	European Association for the Study of Diabetes	Member

COMPETITIVE GRANTS

Year	Title of Grant
2019	sCORRE Cardiovascular Prevention Project - Boehringer Ingelheim

PRIVATE RESEARCH SUPPORT

Investigator Initiated Studies from the following Companies:
Novo Nordisk
Laborest

SCIENTIFIC PRODUCTION

ORCID 0000-0001-8692-8827

Citations 1325

H Index 18

(source www.scopus.com)

MOST SIGNIFICANT PUBLICATIONS (ALL CAREER)

1. **Formoso G.**, Chen H., Kim J.A., Montagnani M., Consoli A., Quon M.J.

- DHEA mimics acute actions of insulin to stimulate production of both NO and ET-1 via distinct PI 3-Kinase- and MAP-Kinase-dependent pathways in vascular endothelium. **Mol Endocrinol. 2006 May; 20(5):1153-63 IF 4.967**
2. Kim J.A., **Formoso G**, Li Y., Potenza M.A., Marasciulo F.L., Montagnani M., and Quon M.J. Epigallocatechin gallate, a green tea polyphenol, mediates NO-dependent vasodilation using signaling pathways in vascular endothelium requiring reactive oxygen species and Fyn. **J Biol Chem. 2007 May 4;282(18):13736-45 IF 5.581**
 3. **Formoso G**, De Filippis E., Michetti N., Di Fulvio P., Pandolfi A., Bucciarelli T., Ciabattini G., Nicolucci A., Davì G., Consoli A.
Decreased in vivo oxidative stress and decreased platelet activation following metformin treatment in newly diagnosed type 2 diabetic subjects. **Diabetes Metab Res Rev. Mar-Apr;24(3):231-7 IF 3.087**
 4. **Andreozzi F.***, **Formoso G.***, Prudente S., Hribal M.L., Pandolfi A., Marini M.A., Di Silvestre S., Trischitta V., Consoli A., Sesti G. ***First two authors equally contributed to the study**
The *TRIB3* R84 Variant Impairs Insulin Signaling-Mediated Nitric Oxide Production in Human Umbilical Vein Endothelial Cells. **Arterioscler Thromb Vasc Biol. 2008 Jul;28(7):1355-60 IF 6.858**
 5. **Formoso G**, Di Tomo P., Andreozzi F., Succurro E., Di Silvestre S., Prudente S., Perticone F., Trischitta V., Sesti G., Pandolfi A., and Consoli A.
TRIB3 R84 Variant is Associated with Increased Carotid Intima- Media Thickness in vivo and with Enhanced MAPK Signaling in Human Endothelial Cells. **Cardiovascular Research, 2011 Jan 189(1):184-92 IF 5.801**
 6. **Formoso G**, Taraborrelli M., Guagnano M.T., D'Adamo M., Di Pietro N., Tartaro A., Consoli A.
Magnetic Resonance Imaging determined Visceral Fat reduction associates with enhanced IL-10 plasma levels in calorie restricted obese subjects.
PLoS ONE 2012;7(12):e52774. doi: 10.1371/journal.pone.0052774. Epub 2012 Dec 26 IF 4.092
 7. Qi L, Qi Q, Prudente S, Mendonca C, Andreozzi F, di Pietro N, Sturma M, Novelli V, Mannino GC, **Formoso G**, Gervino EV, Hauser TH, Muehlschlegel JD, Niewczas MA, Krolewski AS, Biolo G, Pandolfi A, Rimm E, Sesti G, Trischitta V, Hu F, Doria A.
Association between a genetic variant related to glutamic acid metabolism and coronary heart disease in individuals with type 2 diabetes. **JAMA. 2013 Aug 28;310(8):821-8. doi: 10.1001/jama.2013.276305. PMID:23982368 IF 29.978**
 8. Di Fulvio P, Pandolfi A, **Formoso G**, Di Silvestre S, Di Tomo P, Giardinelli A, De Marco A, Di Pietro N, Taraborrelli M, Sancilio S, Di Pietro R, Piantelli M, Consoli A.
Features of endothelial dysfunction in gestational diabetic women umbilical cord vessels. **Nutr Metab Cardiovasc Dis 2014 Dec;24(12):1337-45 IF 3.875**
 9. Di Tomo P, Lanuti P, Di Pietro N, Baldassarre MPA, Marchisio M, Pandolfi A, Consoli A, **Formoso G**.
Liraglutide mitigates TNF- α induced pro-atherogenic changes and Microvesicles release in HUVEC from diabetic women. **Diabetes Metab Res Rev. 2017 Jul 28. doi: 10.1002/dmrr.2925 IF 3.2**
 10. **Formoso G**, Baldassarre MPA, Ginestra F, Carlucci MA, Bucci I, Consoli A.
Inositol and antioxidant supplementation: Safety and efficacy in pregnancy. **Diabetes Metab Res Rev. 2019 Mar 19:e3154. doi: 10.1002/dmrr.3154. Review IF 3.9**

1. Bacci S., Di Paola R., Menzaghi C., Di Fulvio P., Di Silvestre S., Pellegrini F., Baratta R., Marucci A., Mastroianno S, Fini G., **Formoso G.**, Consoli A., Perticone F., Frittitta L., Pandolfi A., Trischitta V. ENPP1 Q121 Variant, Increased Pulse Pressure and Reduced Insulin Signaling, and Nitric Oxide Synthase Activity in Endothelial Cells. **Arterioscler Thromb Vasc Biol. 2009 Aug; 13 Oct;29(10):1678-83 IF 7.235**
2. Santilli F, Formoso G, Sbraccia P, Averna M, Miccoli R, Di Fulvio P, Ganci A, Pulizzi N, Lattanzio S, Ciabattini G, Consoli A, Lauro R, Patrono C, Davì G.
Postprandial hyperglycemia is a determinant of platelet activation in early type 2 diabetes mellitus. **J Thromb Haemost 2010 Apr;8(4):828-37 IF 6.069**
3. **Formoso G.**, Di Tomo P., Andreozzi F., Succurro E., Di Silvestre S., Prudente S., Perticone F., Trischitta V., Sesti G., Pandolfi A., and Consoli A.
TRIB3 R84 Variant is Associated with Increased Carotid Intima- Media Thickness in vivo and with Enhanced MAPK Signaling in Human Endothelial Cells. **Cardiovascular Research, 2011 Jan 189(1):184-92 IF 5.801**
4. Bianchi C, Miccoli R, Bonadonna RC, Giorgino F, Frontoni S, Faloia E, Marchesini G, Dolci MA, Alviggi L, Gnasso A, Consoli A, Cavalot F, Cavallo MG, Leonetti F, Giaccari A, Del Prato S; GENFIEV Investigators (**Formoso G.** member of GENFIEV Investigators).
Metabolic syndrome in subjects at high risk for type 2 diabetes: the genetic, physiopathology and evolution of type 2 diabetes (GENFIEV) study. **Nutr Metab Cardiovasc Dis. 2011 Sep;21(9):699-705. Epub 2010 Nov 5 IF 3.731**
5. **Formoso G.**, Consoli A.
Incretin-based Therapies. **JCMD;2:(1).June2011**
6. Prudente S, Morini E, Larmon J, Andreozzi F, Di Pietro N, Nigro A, Gervino EV, Mannino GC, Bacci S, Hauser TH, Bellacchio E, **Formoso G.**, Pellegrini F, Proto V, Menzaghi C, Frittitta L, Pandolfi A, Sesti G, Doria A, Trischitta V.
The SH2B1 obesity locus is associated with myocardial infarction in diabetic patients and with NO synthase activity in endothelial cells. **Atherosclerosis. 2011 Dec;219(2):667-72. Epub 2011 Aug 19 IF 3.794**
7. Bonomini M., Giardinelli A., Morabito C., Di Silvestre S., Di Cesare M., Di Pietro N., Sirolli V., **Formoso G.**, Amoroso L., Mariggio M.A., Pandolfi A.
The calcimimetic r-568 and its enantiomer s-568 increase nitric oxide release in human endothelial cells. **PLoS ONE. 2012 Jan; 7(1):e30682. Epub 2012 Jan 25 IF 4.092**
8. Liani R, Halvorsen B, Sestili S, Handberg A, Santilli F, Vazzana N, **Formoso G.**, Aukrust P, Davì G.
Plasma levels of soluble CD36, platelet activation, inflammation, and oxidative stress are increased in type 2 diabetic patients. **Free Radic Biol Med. 2012 Apr 15;52(8):1318-24. Epub 2012 Feb 15 IF 5.423**
9. Bianchi C, Miccoli R, Bonadonna RC, Giorgino F, Frontoni S, Faloia E, Marchesini G, Dolci MA, Cavalot F, Cavallo GM, Leonetti F, Del Prato S; GENFIEV Investigators. (**Formoso G.** member of GENFIEV Investigators)
Pathogenetic mechanisms and cardiovascular risk: differences between HbA(1c) and oral glucose tolerance test for the diagnosis of glucose tolerance. **Diabetes Care. 2012 Dec;35(12):2607-12 IF 7.735**
10. Di Pietro N., Di Tomo P., Di Silvestre S., Giardinelli A., Pipino C. Morabito C., **Formoso G.**, Mariggio M.A., Pandolfi A. Increased iNOS activity in Vascular Smooth Muscle Cells from diabetic rats: potential

- role of Ca²⁺/Calmodulin-dependent Protein Kinase II delta 2 (CaMKIIdelta2). *Atherosclerosis*. 2013 Jan;226(1):88-94. doi: 10.1016/j.atherosclerosis.2012.10.062. Epub 2012 Nov 8. IF 3.794
11. **Formoso G**, Taraborrelli M., Guagnano M.T., D'Adamo M., Di Pietro N., Tartaro A., Consoli A. Magnetic Resonance Imaging determined Visceral Fat reduction associates with enhanced IL-10 plasma levels in calorie restricted obese subjects. *PLoS ONE* 2012;7(12):e52774. doi: 10.1371/journal.pone.0052774. Epub 2012 Dec 26. IF 4.092
 12. Consoli A, **Formoso G**
Do thiazolidinediones still have a role in treatment of type 2 diabetes mellitus? *Diabetes Obes Metab*. 2013 Nov;15(11):967-77. doi: 10.1111/dom.12101. Epub 2013 Apr 18 IF. 3.5
 13. Bianchi C, Miccoli R, Trombetta M, Giorgino F, Frontoni S, Faloia E, Marchesini G, Dolci MA, Cavalot F, Cavallo G, Leonetti F, Bonadonna RC, Del Prato S; GENFIEV Investigators.
Elevated 1-hour postload plasma glucose levels identify subjects with normal glucose tolerance but impaired β -cell function, insulin resistance, and worse cardiovascular risk profile: the GENFIEV study. (**Formoso G**, member of GENFIEV Investigators). *J Clin Endocrinol Metab*. 2013 May;98(5):2100-5. doi: 10.1210/jc.2012-3971. Epub 2013 Mar 28 IF 6.43
 14. Qi L, Qi Q, Prudente S, Mendonca C, Andreozzi F, di Pietro N, Sturma M, Novelli V, Mannino GC, **Formoso G**, Gervino EV, Hauser TH, Muehlschlegel JD, Niewczas MA, Krolewski AS, Biolo G, Pandolfi A, Rimm E, Sesti G, Trischitta V, Hu F, Doria A.
Association between a genetic variant related to glutamic acid metabolism and coronary heart disease in individuals with type 2 diabetes. *JAMA*. 2013 Aug 28;310(8):821-8. doi: 10.1001/jama.2013.276305. PMID:23982368 IF 29.978
 15. Lattanzio S, Santilli F, Liani R, Vazzana N, Ueland T, Di Fulvio P, **Formoso G**, Consoli A, Aukrust P, Davi G.
Circulating dickkopf-1 in diabetes mellitus: association with platelet activation and effects of improved metabolic control and low-dose aspirin. *J Am Heart Assoc*. 2014 Jul 18;3(4). pii: e001000. doi: 10.1161/JAHA.114.001000 IF 2.882
 16. Di Fulvio P, Pandolfi A, **Formoso G**, Di Silvestre S, Di Tomo P, Giardinelli A, De Marco A, Di Pietro N, Taraborrelli M, Sancilio S, Di Pietro R, Piantelli M, Consoli A.
Features of endothelial dysfunction in gestational diabetic women umbilical cord vessels. *Nutr Metab Cardiovasc Dis* 2014 Dec;24(12):1337-45 IF 3.875
 17. Consoli A, **Formoso G**.
Potential side effects to GLP-1 based agonists: understanding their safety and tolerability. *Expert Opin Drug Saf*. 2014 Dec 12;1-12 IF 2.735
 18. Di Tomo P, Di Silvestre S, Cordone VG, Giardinelli A, Faricelli B, Pipino C, Lanuti P, Peng T, **Formoso G**, Yang D, Arduini A, Chiarelli F, Pandolfi A, Di Pietro N
Centella asiatica and lipoic acid, or a combination thereof, inhibit monocyte adhesion to endothelial cells from umbilical cords of gestational diabetic women. *Nutr Metab Cardiovasc Dis*. 2015 Jul;25(7):659-66 IF 3.875
 19. Di Pietro N, **Formoso G**, Pandolfi A.
Physiology and pathophysiology of oxLDL uptake by vascular wall cells in atherosclerosis. *Vascul Pharmacol*. 2016 Sep;84:1-7. doi: 10.1016/j.vph.2016.05.013. Epub 2016 May 30. Review IF 2.3

20. Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, Steinberg WM, Stockner M, Zinman B, Bergenstal RM, Buse JB; LEADER Steering Committee; LEADER Trial Investigators. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. **N Engl J Med. 2016 Jul 28;375(4):311-22. doi: 10.1056/NEJMoa1603827. Epub 2016 Jun 13 IF 72**
21. Halvorsen B, Santilli F, Scholz H, Sahraoui A, Gulseth HL, Wium C, Lattanzio S, **Formoso G**, Di Fulvio P, Otterdal K, Retterstøl K, Holven KB, Gregersen I, Stavik B, Bjerkeli V, Michelsen AE, Ueland T, Liani R, Davi G, Aukrust P. LIGHT/TNFSF14 is increased in patients with type 2 diabetes mellitus and promotes islet cell dysfunction and endothelial cell inflammation in vitro. **Diabetologia. 2016 Oct;59(10):2134-44. doi: 10.1007/s00125-016-4036-y. Epub 2016 Jul 15 IF 6**
22. Santilli F, Liani R, Di Fulvio P, **Formoso G**, Simeone P, Tripaldi R, Ueland T, Aukrust P, Davi G. Increased circulating resistin is associated with insulin resistance, oxidative stress and platelet activation in type 2 diabetes mellitus. **Thromb Haemost. 2016 Oct 6;116(6) IF 5.6**
23. Di Tomo P, Lanuti P, Di Pietro N, Baldassarre MPA, Marchisio M, Pandolfi A, Consoli A, Formoso G. Liraglutide mitigates TNF- α induced pro-atherogenic changes and Microvesicles release in HUVEC from diabetic women. **Diabetes Metab Res Rev. 2017 Jul 28. doi: 10.1002/dmrr.2925 IF 3.2**
24. Fadini GP, Zatti G, Consoli A, Bonora E, Sesti G, Avogaro A; DARWIN-T2D Network (**Formoso G**, member of the DARWIN-T2D Network). Rationale and design of the DARWIN-T2D (Dapagliflozin Real World evldeNce in Type 2 Diabetes): A multicenter retrospective nationwide Italian study and crowdsourcing opportunity. **Nutr Metab Cardiovasc Dis. 2017 Dec;27(12):1089-1097. doi: 10.1016/j.numecd.2017.08.001. Epub 2017 Aug 8 IF 3.7**
25. Consoli A, **Formoso G**, Baldassarre MPA, MD, Febo F. A Comparative Safety Review between GLP-1 Receptor Agonists and SGLT2 Inhibitors for Diabetes Treatment. **Expert Opin Drug Saf. 2018 Mar;17(3):293-302 IF 3.4**
26. **Formoso G**, Ginestra F, Di Dalmazi G, Consoli A. Empagliflozin, metformin and insulin degludec, during pregnancy: a case report. **Acta Diabetol. 2018 Mar 29 IF 3.3**
27. Di Tomo P, Di Pietro N, Mandatori D, Pipino C, **Formoso G**, Napolitano A, Palumbo A, Pandolfi A. Anti-Inflammatory Activity of Marine Ovothiol A in an In Vitro Model of Endothelial Dysfunction Induced by Hyperglycemia. **Oxidative Medicine And Cellular Longevity IF 5.7**
28. Fadini GP, Bottigliengo D, D'Angelo F, Cavalot F, Bossi AC, Zatti G, Baldi I, Avogaro A; DARWIN-T2D Network. Comparative Effectiveness of DPP-4 Inhibitors Versus Sulfonylurea for the Treatment of Type 2 Diabetes in Routine Clinical Practice: A Retrospective Multicenter Real-World Study. **Diabetes Ther. 2018 Jun 1. doi: 10.1007/s13300-018-0452-y IF 2.37**
29. Fadini GP, Solini A, Manca ML, Zatti G, Karamouzis I, Di Benedetto A, Frittitta L, Avogaro A; DARWIN-T2D Network. Phenotyping normal kidney function in elderly patients with type 2 diabetes: a cross-sectional multicentre study. **ActaDiabetol. 2018 Nov;55(11):1121-1129. doi: 10.1007/s00592-018-1194-z. Epub 2018 Aug 9 IF 3.12**

30. **Formoso G**, Baldassarre MPA, Ginestra F, Carlucci MA, Bucci I, Consoli A.
Inositol and antioxidant supplementation: Safety and efficacy in pregnancy. ***Diabetes Metab Res Rev.*** **2019 Mar 19:e3154. doi: 10.1002/dmrr.3154. Review IF 3.9**

31. Fadini GP, Sciannameo V, Franzetti I, Bottigliengo D, D'Angelo P, Vinci C, Berchiolla P, Arena S, Buzzetti R, Avogaro A; DARWIN-T2D network.
Similar effectiveness of dapagliflozin and GLP-1 receptor agonists concerning combined endpoints in routine clinical practice A multicentre retrospective study. ***Diabetes Obes Metab.*** **2019 Apr 15. doi: 10.1111/dom.13747 IF 5.98**

32. Muscogiuri G, **Formoso G**, Pugliese G, Ruggeri RM, Scarano E, Colao A; RESTARE.
Prader- Willi syndrome: An uptodate on endocrine and metabolic complications. ***Rev Endocr Metab Disord.*** **2019 May 7. doi: 10.1007/s11154-019-09502-2. Review IF 4.96**

33. Fadini GP, Li Volsi P, Devangelio E, Poli M, Cazzetta G, Felace G, Avogaro A; DARWIN-T2D Network. Network (**Formoso G**, member of the DARWIN-T2D Network)
Predictors of early discontinuation of dapagliflozin versus other glucose-lowering medications: a retrospective multicenter real-world study. ***J Endocrinol Invest.*** **2019 Sep 12. doi: 10.1007/s40618-019-01110-w IF 3.2**

34. Santilli F, Zaccardi F, Liani R, Petrucci G, Simeone P, Pitocco D, Tripaldi R, Rizzi A, **Formoso G**, Pontecorvi A, Angelucci E, Pagliaccia F, Golato M, De Leva F, Vitacolonna E, Rocca B, Consoli A, Patrono C.
In vivo thromboxane-dependent platelet activation is persistently enhanced in subjects with impaired glucose tolerance. ***Diabetes Metab Res Rev.*** **2019 Oct 31:e3232. doi: 10.1002/dmrr.3232 IF 3.9**

35. Sciannameo V, Berchiolla P, Orsi E, Lamacchia O, Morano S, Querci F, Consoli A, Avogaro A, Fadini GP; DARWIN-T2D study. (**Formoso G**, member of the DARWIN-T2D Network)
Enrolment criteria for diabetes cardiovascular outcome trials do not inform on generalizability to clinical practice. The case of GLP-1 receptor agonists. ***Diabetes Obes Metab.*** **2020 Jan 14. doi: 10.1111/dom.13962 IF 5.98**